Clinical applications of mifepristone

Oi Shan Tang, Tang OS, Ho PC, Pak Chung Ho
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2006 · vol. 22(12) , pp. 655–659 · doi:10.1080/09513590601005946 · PMID:17162706 · W1984252593
Review OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Mifepristone, a progesterone antagonist, is an effective abortifacient, cervical priming agent, and emergency contraceptive, with explored applications in fibroids, endometriosis, and cancer, though its abortion association limits broader use.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog. It is also an effective cervical priming agent that can be used to soften the cervix before surgical evacuation. Its clinical efficacy as an emergency contraception has been proven. Other applications including treatment for fibroids, endometriosis and various cancers have been explored. However, its association with abortion limits the applications of mifepristone in many of these areas.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Abortifacient Agents, Steroidal Abortion, Induced Mifepristone Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortion, Induced Abortion, Induced Abortion, Spontaneous Abortion, Spontaneous Abortion, Spontaneous Contraceptive Agents Contraceptive Agents Contraceptive Agents Contraceptive Agents Female Female Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (51)

Cited by (6)

Source provenance

europepmc
last seen: 2026-10-10T06:11:15.153948+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:04:05.892929+00:00
License: CC0 · commercial use OK